SALT LAKE CITY, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced an agreement with Hannah Storm, a nationally renowned sports broadcaster, who recently revealed her battle with breast cancer. Under the agreement, Storm will act as an ambassador for the Myriad Genetics Breast Cancer Risk Assessment Program featuring the MyRisk® with RiskScore® Hereditary Cancer Test, the first and industry-leading hereditary cancer test and ...

News release updated to include the members of the management team speaking at the conference. SALT LAKE CITY, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Paul J. Diaz, President and CEO, and Sam Raha, COO, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 15, at 3:45pm PT (6:45pm ET). The presentation will be available through a live webcast in the investor rel ...

SALT LAKE CITY, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced members of its management team will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 15, at 3:45pm PT (6:45pm ET). The presentation will be available through a live webcast in the investor relations section of Myriad’s website at investor.myriad.com. An archived edition of the presentation will be available ...

HOUSTON and SALT LAKE CITY, Jan. 07, 2025 (GLOBE NEWSWIRE) -- The University of Texas MD Anderson Cancer Center and Myriad Genetics, Inc. today announced a five-year strategic alliance to accelerate the clinical evaluation and development of Myriad’s molecular residual disease (MRD) assay. This strategic alliance brings together the longstanding oncology diagnostic experience of Myriad Genetics and the clinical and translational research expertise of MD Anderson to create a portfolio of studies to evaluate ...

SALT LAKE CITY, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its Quality, Innovation, and Corporate Responsibility Report, highlighting key efforts that reflect its commitment to conduct operations as a responsible corporation in the healthcare industry. “Quality, innovation and corporate responsibility are at the heart of what we do at Myriad Genetics,” said Paul J. Diaz, President and CEO, Myriad Genetics. “In co ...

SALT LAKE CITY, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic testing and precision medicine, announced that a MyRisk® Hereditary Cancer Test with RiskScore® study has been named in the American Journal of Human Genetics as one of its top 10 significant advances in genomic medicine. The study was selected by the Genomic Medicine Working Group at the National Human Genome Research Institute. The study by Mabey et al., “Validation of a clinical breast ...

SALT LAKE CITY, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic and genomic testing and precision medicine, announced that a MyRisk® Hereditary Cancer Test with RiskScore® study has been named in the American Journal of Human Genetics as one of its top 10 significant advances in genomic medicine. The study was selected by the Genomic Medicine Working Group at the National Human Genome Research Institute. The study by Mabey et al., "Validation of a clinical breast c ...

Myriad Genetics, Inc. (MYGN) is driving innovation across Oncology, Women's Health and Pharmacogenomics, and heavily invests in labs and digital capabilities. Thecompany’s Oncology growth strategy centers on the expansion of companion diagnostics, market expansion through new clinical guidelines and the introduction of new offerings. In addition, key partnerships, such as with GSK and QIAGEN, underscore its commitment to improving access to HRD diagnostic testing. Yet, a volatile macroeconomic situation and ...

Myriad Genetics, Inc. (MYGN) recently announced updates to its agreement with Illumina Inc. (ILMN) . The company’s gold-standard Genomic Instability Score (“GIS”) to determine Homologous Recombination Deficiency (“HRD”) will be reported for all samples analyzed with Illumina’s updated research assay, TruSight Oncology 500 v2 (TSO 500 v2).The latest development expands the worldwide access to Myriad Genetics’ GIS, previously available as a separate product, and better positions it as a potential companion di ...

Myriad Genetics, Inc. (MYGN) recently made SneakPeek available over the counter in more than 8,800 retail locations nationwide. SneakPeek is the first at-home early fetal sex test for use at six weeks, now available on shelves in Walmart, Walgreens and CVS stores. Through the SneakPeek test, Myriad Genetics is on a mission to make DNA-based prenatal information affordable and accessible for all families.MYGN Stock Movement Following the NewsFollowing the news, shares of MYGN fell 2.4% to $15.78 at yesterday ...